NCT06067776View on ClinicalTrials.gov

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

November 1, 2026

Conditions
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Cetuximab

Given IV

DRUG

Osimertinib

Given PO

DRUG

Tucatinib

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jonathan Riess

OTHER

NCT06067776 - Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | Biotech Hunter | Biotech Hunter